Immunoscintigraphic detection of tumour necrosis factor by radiolabelled certolizumab pegol in patients with erosive hand osteoarthritis: a proof-of-concept study

Ann Rheum Dis. 2018 Feb;77(2):310-311. doi: 10.1136/annrheumdis-2016-210354. Epub 2016 Dec 8.

Authors

Ruth Wittoek¹, Philippe Carron¹, Bieke Lambert^{2

3}, Paulien Meersseman¹, Gust Verbruggen¹, Filip Van den Bosch¹, Dirk Elewaut^{1

4}

Affiliations

¹ Department of Rheumatology, Ghent University Hospital, Ghent, Belgium.
² Department of Radiology and Nuclear Medicine, Ghent University, Ghent, Belgium.
³ Department of Nuclear Medicine, AZ Maria Middelares, Ghent, Belgium.
⁴ VIB Inflammation Research Center, Ghent University Hospital, Ghent, Belgium.

PMID: 27932347
DOI: 10.1136/annrheumdis-2016-210354

No abstract available

Keywords: DMARDs (biologic); Hand Osteoarthritis; TNF-alpha.

Publication types

Letter
Research Support, Non-U.S. Gov't

MeSH terms

Certolizumab Pegol / administration & dosage*
Female
Hand / diagnostic imaging*
Hand / pathology
Humans
Male
Middle Aged
Osteoarthritis / diagnostic imaging*
Radioimmunodetection / methods*
Tumor Necrosis Factor-alpha / metabolism*

Substances

Tumor Necrosis Factor-alpha
Certolizumab Pegol